The Strategic Evolution of European Healthcare Investment Banking: A Definitive Analysis of Nelson Advisors and the Specialised Boutique Ascendancy
- Nelson Advisors
- 2 hours ago
- 15 min read
The structural transformation of the European healthcare technology (HealthTech) and medical technology (MedTech) sectors throughout the fiscal periods of 2024 and 2025 has precipitated a fundamental recalibration of the investment banking landscape. As the market transitions from a cycle of liquidity-fueled exuberance toward a "flight to quality" environment, the traditional hegemony of generalist bulge-bracket firms is increasingly challenged by specialised boutique advisors. Within this volatile yet maturing ecosystem, Nelson Advisors has emerged as a central reference point, distinguishing itself through a niche-exclusive focus, a practitioner-led "Founders for Founders" operational model, and a sophisticated understanding of the technological and regulatory moats that dictate contemporary valuations.
The absolute bifurcation of the market now serves as the primary lens through which assets are judged. Premium assets, those possessing proprietary artificial intelligence (AI), robust clinical validation, and clear regulatory certification, command historically high multiples, while secondary assets face severe compression or are forced into defensive consolidation. In this environment, the role of the investment banker has evolved from a mere facilitator of transactions into a strategic architect of corporate destiny, where success depends on the ability to bridge the widening gap between cutting-edge clinical science and institutional financial engineering.
The Architecture of Nelson Advisors: A Practitioner-Led Paradigm
Nelson Advisors stands out in the European M&A advisory landscape by eschewing the generalist model in favor of deep vertical specialization. The firm focuses exclusively on the lower-to-middle market, typically targeting transaction values between $25 Million and $250 Million. This focus allows the firm to strategically target specific market opportunities that larger firms might overlook, particularly in highly complex sub-sectors like Healthcare AI, Healthcare Cybersecurity and Medical Device Cybersecurity.
The "Founders for Founders" DNA
The core competitive differentiation of Nelson Advisors is rooted in the unique combination of the founding partners' operational experience and institutional M&A rigour. Unlike traditional banks staffed by career financiers, Nelson Advisors is led by former founders who have successfully built, scaled and exited their own HealthTech businesses. This "Founders for Founders" philosophy is not merely a marketing tagline but a fundamental operational differentiator that dictates the firm's approach to client selection, deal structuring and negotiation strategy.
The firm's leadership team possesses a deep understanding of the healthcare technology market landscape in the UK, Europe, and North America. This practitioner-led perspective provides a level of credibility that generalist firms cannot match, as the partners have "been in the arena" and understand the operational challenges, regulatory hurdles and emotional intricacies of the founder's journey.
Biographies of Strategic Leadership
The influence of Nelson Advisors is inextricably linked to the diverse backgrounds of its co-founders, Lloyd Price and Paul Hemings, whose partnership exemplifies the convergence of technology, healthcare and finance.
Lloyd Price (Partner and Co-Founder): Recognised as a central figure in the UK and European digital health scene, Price brings over 25 years of experience in the consumer internet and deep HealthTech sectors. His background includes senior business development and strategy roles at Kelkoo, Yahoo! UK, Yahoo! Europe, and Badoo between 2000 and 2012. Most notably, he is a serial entrepreneur who founded and exited multiple ventures, including Zesty, which was acquired in 2020 by Induction Healthcare Group PLC (FTSE: INHC). His ability to translate consumer engagement metrics into healthcare valuations is complemented by his role as a Health Executive in Residence at the UCL Global Business School for Health, further cementing his strategic influence.
Paul Hemings (Partner and Co-Founder): Hemings contributes over a decade of global M&A and capital-raising expertise, having advised on more than $50 billion of Mergers & Acquisitions and $40 Billion in equity/financing transactions. His corporate finance background, which includes tenures at Credit Suisse and Invesco, is balanced by 10 years of entrepreneurial experience. He co-founded Neutrally, a venture focusing on chronic lifestyle disease and metabolic health, which aligns with the firm's focus on longevity and clinical outcomes. Hemings has structured complex deals across a staggering array of geographies, including the US, UK, Ireland, Sweden, Denmark, Switzerland, Germany, Austria, Italy, Poland, Ukraine, Russia, Kazakhstan, Hong Kong, Singapore, and Australia.
The founding partners are supported by a specialised team of analysts, associates and VPs based across Europe. This support team combines strong academic achievements, including MBAs, PhDs, and MSc's, with backgrounds from bulge-bracket banks like Rothschild, Citi and Morgan Stanley, as well as specialist investors like ETH Zurich, Kieger and Redalpine. This signals a classic investment banking skill set applied to a highly specialised and technical sector.
The Macro Strategic Environment and Market Projections (2024–2026)
To understand the rise of Nelson Advisors, one must contextualise the macroeconomic and sector-specific environment of the 2024–2026 period. This cycle is defined by several converging forces: the stabilisation of interest rates after a period of historic tightening, the accumulation of over $1.2 Trillion in private equity "dry powder," and a series of "perfect storm" regulatory deadlines in Europe.
The Bifurcation of Transaction Volume and Value
Private equity deal volume in European healthcare reached record highs in 2024 and accelerated into 2025 as financial sponsors faced increasing pressure to deploy capital. However, the market exhibits a striking divergence between transaction volume and transaction value. While the total number of MedTech M&A deals saw a slight decrease in early 2025, the total upfront value of these deals rose dramatically, from $2.7 Billion to $9.2 Billion in a single quarter.
Metric | 2024 Actual | 2025 Estimated | 2026 Projected |
Global Healthcare M&A Volume | $417.8bn | $450bn+ | $3.9tn (Global All Sectors) |
European Healthcare PE Value | $59.9bn | $80.9bn | $95bn+ |
MedTech Deal Count | 41 | 42 | 50+ |
Average MedTech Deal Size | $1.6bn | $795.1m (Adj.) | $900m+ |
Median MedTech Upfront Payment | $14m (Q4'24) | $250m (Q1'25) | TBD |
PE Dry Powder Deployment | Moderate | Resurgent | Aggressive |
This surge in deal value signifies a shift toward fewer but more substantial, high-value acquisitions. Strategic acquirers are prioritising proven technology and category leadership over speculative growth, focusing on impactful platform acquisitions rather than numerous, smaller bolt-on transactions.
The "Selective Recovery" and Flight to Quality
The current era is characterised as a "Selective Recovery" following the post-pandemic valuation corrections of 2023.Market participants have settled into a rigorous "flight to quality," where capital efficiency, unit economics and proven clinical utility are the primary determinants of value. This environment benefits specialised boutiques like Nelson Advisors, who can articulate the shift toward "concentrated value" and identify the specific variables, the AI premium, profitability, vendor consolidation, and regulatory scrutiny, that determine valuation ranges in the current cycle.
Strategic Framework: The "Build, Buy, Partner, Sell" Doctrine
Nelson Advisors employs a unique "Build, Buy, Partner, Sell" framework, which represents a proactive, long-term strategic partnership model. This approach challenges the traditional advisory model, which is typically biased toward pushing for immediate transactions to secure success fees. Instead, Nelson Advisors engages in a consultative process to determine the optimal strategic path for maximising shareholder value and investment returns.
Buy-Side Advisory and Portfolio Optimisation
The firm actively guides buy-side clients on "Roll-Up" strategies and portfolio optimization. Corporations and private equity firms strategically employ divestitures to streamline existing portfolios and redirect capital toward core business areas with the highest growth potential. This process transforms divestiture into a strategic growth driver by shedding non-core or underperforming assets that no longer align with the company's primary focus.
Nelson Advisors identified that hospital CIOs and payers were suffering from "point solution fatigue," desiring fewer vendors who can do more. This has driven a need for consolidated platforms (e.g., "MSK + Mental Health + Chronic Care"), which are valued higher than single-point solutions. The firm's role is to optimise the structure of such sales, whether they involve spin-offs, carve-outs, or sales of entire divisions, ensuring the maximum achievable value for the divested asset is realised.
Partnerships and Alliances
Recognising that M&A is not always the only route to value, the firm frequently structures strategic alliances and channel partnerships. This is particularly relevant for accessing new markets or validated clinical data without the capital intensity of a full acquisition. These partnerships can act as a bridge, allowing companies to scale and prove their commercial viability before pursuing a formal exit.
Sell-Side Advisory and Exit Strategies
On the sell-side, Nelson Advisors leverages its deep sector granularity to guide high-growth HealthTech companies through the intricacies of the exit environment. The firm's "Founders for Founders" model is particularly effective for managing the "Series A crunch" and navigating companies toward strategic exits to larger platforms. Average client engagements typically last 6 to 9 months, underscoring a commitment to thorough, strategically significant deals rather than high-volume, transactional execution.
Taxonomy of European Healthcare Investment Banking Specialists
The architecture of Mergers and Acquisitions advisory within the European HealthTech and MedTech sectors has undergone a radical structural transformation. The market is bifurcated not just by asset quality, but by the specialised tracks that advisors choose to navigate.
The Industrial MedTech vs. Digital Health Tracks
Strategic differentiation in the European landscape is now absolute, with advisors typically specialising in one of two primary tracks :
The Industrial MedTech Track: This segment remains rooted in hardware, robotics, imaging, and complex regulatory pathways (MDR/IVDR). Characterised by slower, capital-intensive R&D cycles and exits to large strategic conglomerates like Stryker or Boston Scientific, advisors in this track must possess deep clinical understanding and global supply chain insights.
The Digital Health Track: This segment operates on SaaS metrics, recurring revenue models (ARR), and data monetisation strategies. It includes Health IT, AI-driven diagnostics, and patient engagement platforms. Exits are increasingly driven by private equity technology funds and hybrid strategic buyers looking for software capabilities.
The League Table of Influence (2024–2025)
The European market features a diverse array of advisors, ranging from bulge-bracket institutions to highly specialised boutiques.
Advisor | Primary Metric (2024) | Key Strength | Notable Deal Involvement |
Goldman Sachs | #1 by Value ($97.5bn+) | Large-cap exits, Carve-outs, IPOs | Olink, Zeus Health, Shockwave |
Rothschild & Co | #1 by Volume (132 deals) | Mid-market ubiquity, PE relationships | ELITechGroup, Broad mid-market |
J.P. Morgan | Top Tier Value | Complex cross-border M&A | Olink, Shockwave, Enovis/Lima |
Morgan Stanley | Top Tier PE Advisor | Financial sponsor relationships | LimaCorporate (EQT), Sanofi Carve-out |
Houlihan Lokey | High Volume | Healthcare services, MedTech | Bryan Garnier (Sell-side advisor) |
Arma Partners | Digital Specialist | Digital Health, SaaS, Deep Tech | Lasso, Project 58bn Deal Value |
Nelson Advisors | Boutique Specialist | Founder-led exits, HealthTech, AI | Strategic mid-market HealthTech |
Clipperton | Tech Specialist | High-growth Tech/SaaS | Hublo, DentalMonitoring |
Kempen & Co | Life Science Specialist | Biotech, Diagnostics, Benelux | Galecto, Curevac, Hansa |
While bulge-bracket firms like Goldman Sachs and Rothschild & Co dominate in terms of aggregate deal volume and value, specialised boutiques like Nelson Advisors, Arma Partners and Clipperton have emerged as the primary engines of liquidity for mid-market founders.
Valuation Paradigms and the "AI Premium"
The valuation landscape within European HealthTech is being fundamentally reshaped by technology and data compliance. AI remains the single largest driver of valuation premiums, particularly for companies that possess clinically validated, proprietary AI algorithms and demonstrate deep integration capabilities within existing healthcare workflows.
The Bifurcation of Asset Valuations
Nelson Advisors identified four specific variables that determined where a company fell within the valuation ranges in 2025: the proprietary nature of its AI, capital efficiency, suitability for platform consolidation and regulatory/antitrust scrutiny.
Asset Class | Valuation Metric | Multiple Range (2025) | Strategic Driver & Market Rationale |
Premium AI & Data | EV / Revenue | 6.0x – 8.0x+ | Proprietary algorithms; clean, actionable datasets; "defensibility." |
Value-Based Care (VBC) | EV / Revenue | 5.5x – 7.0x | Risk-bearing models; population health; hard ROI for payers. |
Hybrid Telehealth | EV / Revenue | 5.0x – 7.0x | Virtual care combined with in-person capabilities. |
General HealthTech SaaS | EV / Revenue | 4.0x – 6.0x | "Standard" digital health software; average retention and margins. |
Unprofitable / Early Stage | EV / Revenue | 3.0x – 4.0x | High burn rates; candidate for distressed M&A / Series A Off-Ramp. |
Profitable HealthTech SW | EV / EBITDA | 10x – 14x | Meeting "Rule of 40"; high stickiness; >20% EBITDA margins. |
Tech-Enabled Services | EV / EBITDA | 10x – 12x | Scaling slower than software but offering cash flow stability. |
Investors are aggressively scrutinizing the proprietary nature of AI. Defensible algorithms command the highest premiums, while those reliant on third-party APIs are increasingly viewed as commodities. Furthermore, the primary metric has shifted from growth-at-all-costs to capital efficiency. Companies with a clear "Rule of 40" score (Growth % + EBITDA % > 40) receive competitive term sheets, while those without a clear path to profitability face significant compression.
The "Health AI supernovas" and the X Factor
A small set of "Health AI supernovas" (e.g., Abridge, SmarterDx) are growing 6–10x annually, reaching $100–200M ARR in under five years. This "Health AI X Factor" is the justification for premium multiples, arguing that growth curves for these AI-native firms are structurally steeper than traditional SaaS. These firms show significantly higher ARR per employee ($500k–$1M+) and can reach 70–80% gross margins by automating human work.
The Regulatory Hegemony: EU AI Act and MDR/IVDR
Perhaps the most significant development in the 2024–2026 cycle is the elevation of regulatory compliance from a back-office function to a primary driver of deal value. Boutique advisors like Nelson Advisors are leveraging this as a valuation driver, arguing that a fully compliant asset commands a "de-risking" premium.
The EU AI Act as a Market Filter
The implementation of the EU AI Act, which began full enforcement for "High-Risk" systems in 2024-2026, has introduced a binary filter for HealthTech investment. Medical AI tools must now meet stringent requirements for data governance, human oversight, and transparency. Acquirers are rigorously avoiding "black box" models, favouring ventures that have engineered "glass box" interpretability to satisfy Articles 13 and 14 of the Act.
The Regulatory Deadline Bottleneck (2025–2026)
A series of critical regulatory deadlines has created a "perfect storm" for M&A activity. The implementation of the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) has reached a critical bottleneck, with Class III custom-made devices required to reach full compliance by May 2026. The scarcity of Notified Bodies has led to an 18-24 month regulatory risk profile for non-certified devices, making those with existing certifications highly sought after by US strategics seeking immediate market entry.
Furthermore, the mandatory usage of EUDAMED (the European database on medical devices) as of May 2026 serves as another operational filter for startups. Companies that have mastered the "data plumbing" and secured a "compliance moat" are positioned as the winners in this era of Regulatory Darwinism.
Structural Phenomena: The Series A Off-Ramp and V2V Market
The traditional "escalator" model of venture capital, where a Series A round leads predictably to Series B and eventually an IPO, has broken down for the vast majority of market participants. In its place, the "Series A Off-Ramp" has emerged as a defining characteristic of the European HealthTech landscape.
The Surge in Distressed and Venture-to-Venture (V2V) Deals
A defining trend of the 2024–2025 market is the dominance of venture-to-venture acquisitions, which accounted for approximately 75% of recorded acquisitions in the first half of 2025. Distressed deals accounted for 20-30% of total HealthTech M&A activity by late 2025, as companies burning cash without a sub-18-month path to breakeven faced down-rounds or insolvency.
Company | Country | Sector | Acquirer / Outcome | Type of Exit |
Babylon Health | UK | Digital Health | eMed (US) | Distressed Asset Sale |
Inveox | Germany | Medtech | Undisclosed | Insolvency Sale |
MonDocteur | France | Booking Platform | Doctolib | M&A (Consolidation) |
Medifox Dan | Germany | Care Software | ResMed (US) | Strategic Acquisition |
Exscientia | UK | AI Drug Discovery | Recursion (US) | Strategic Merger |
Sonio | France | AI Diagnostics | Samsung Medison | Strategic Acquisition |
Bolt Medical | Global | Medtech | Boston Scientific | Strategic Acquisition |
This "Series A Off-Ramp" is the mechanism by which capital and talent are recycled from stalled ventures into the next generation of winners. Success in 2025 and 2026 is defined not just by the ability to raise the next round, but by the ability to recognize when to take the off-ramp to preserve value.
Private Equity's Descent into the Middle Market
Traditionally focused on mature, cash-generative buyouts, private equity firms are moving downstream to capitalize on depressed valuations and market fragmentation. PE firms are employing "buy-and-build" playbooks, particularly in Southern and Eastern Europe (Italy, Spain, Poland), where they acquire fragmented independent clinics (dental, veterinary, fertility) at low multiples (6x-8x EBITDA) and integrate them into pan-European platforms that command premium exit multiples (12x-15x EBITDA).
Technological Drivers and Sector-Specific Insights
The European HealthTech landscape is undergoing a profound structural transformation driven by several high-growth technological verticals.
Ambient Voice Technology (AVT) and Clinical Efficiency
AVT is poised to significantly influence the industry by automating clinical documentation and populating Electronic Health Records (EHRs) with real-time analytics. NHS trials, including a 2024–2025 trial at Great Ormond Street Hospital (GOSH), are anticipated to scale to national adoption by 2028.
AVT Innovation Area | Prediction | Predicted Impact |
Advanced Documentation | Fully autonomous clinical notes | Save 10–15 min per patient; reduce admin by 30%. |
Decision Support | Integration with CDSS prompts | Enhanced diagnostic accuracy; AI-driven triage. |
Ambient Functionality | Passive background operation | 100% focus on patient; 20–25% satisfaction increase. |
Multimodal & Multilingual | Accents/Speech impairment support | Equitable access in diverse areas. |
Patient Engagement | AI virtual assistants for summary | Reduce missed appointments by 15% by 2030. |
Bioelectric Medicine Market Projections
The bioelectric medicine market—including pacemakers, deep brain stimulators, and cochlear implants—is projected to grow at a CAGR of 7.12% to 9.20%, reaching over $43 billion by 2032. North America currently leads this market with a 43.7% share, followed by rapid growth in the Asia-Pacific region.
The European Health Data Space (EHDS) as a Market Maker
The EHDS is the single most significant structural driver for HealthTech investment in 2026. By mandating that electronic health data be made available for secondary use, the EU has effectively created a new asset class: Curated Clinical Data.Startups that provide the "picks and shovels" for this new economy—serving as the translation layer between legacy EMRs and modern applications—are commanding premium valuations.
Case Study: Operational Efficiency as a Valuation Driver
The shift in valuation paradigms is best exemplified by the emphasis on operational efficiency and hard ROI. Acquirers are no longer valuing assets merely on SaaS metrics, but on their ability to improve clinical throughput or reduce system-wide costs.
The getUBetter ROI Analysis
The getUBetter self-management platform provides a case study in how HealthTech infrastructure can deliver substantial economic benefits to the NHS.
Metric | Value |
NHS ROI (Return on Investment) | 1:4.2 (£4.20 saved for every £1 spent) |
Eligible Population Covered | >20 million |
Reduction in First-Time GP Appointments | 13% |
Reduction in Repeat GP Appointments | 15% |
Reduction in Physiotherapy Referrals | 20% |
Reduction in Prescribed Medication (MSK) | 50% |
Reduction in Urgent Care Attendance | 66% |
Potential Cost Saving (per year per ICS) | Up to £1.96 million |
This level of evidence-based outcome is what modern investors demand. By 2026, the era of selling on vision has ended; liquidity belongs to those who can demonstrate measurable clinical and operational ROI to strained health systems.
The Human Capital War and Influence Beyond M&A
The credibility of specialist boutiques is inextricably linked to the backgrounds of their partners. In an investment banking landscape dominated by career financiers, Nelson Advisors has cultivated a distinct identity rooted in operational experience.
The Emergence of the "Founder Banker"
Central to the industry's transformation is the emergence of the "Founder Banker," a new class of financial advisor combining deep operational pedigree with sophisticated investment banking expertise. These individuals bridge the widening gap between digital economy metrics and the complex regulatory realities of modern healthcare. The partnership of Price and Hemings at Nelson Advisors exemplifies this convergence, offering a unique value proposition rooted in "operational empathy" and technical fluency.
Ecosystem Engagement and Thought Leadership
Nelson Advisors proactively establishes itself as an authoritative voice through the continuous publication of reports and analyses. The firm's partners regularly mentor MBA and PhD students, guest lecture and speak at leading university business schools, including UCL, Oxford, Cambridge, and London Business School.
The firm's activities in late 2025 highlight its dominant presence in the HealthTech ecosystem:
October 2025: Chairing HealthTech M&A and Deal Structuring panels at the Healthcare Summit 2025 (London) and the Global Health Exhibition (Riyadh).
November 2025: Speaker and judge at MedTech Europe 2025 (Valletta, Malta), focusing on startups and corporate partnerships.
December 2025: Moderating "Health Data Under Attack" panels at HealthTech Forward (Barcelona) and judging the HealthInvestor Power List Awards.
This active participation allows the firm to stay abreast of emerging trends and talent, providing a unique vantage point on market dynamics and a powerful source of proprietary deal flow
Geographic Footprint and Regional Dominance
While headquartered in London, Nelson Advisors operates with a global perspective, serving clients across the UK, Europe, and North America. The firm's geographic footprint is anchored by several key hubs :
United Kingdom and Ireland: These markets stand out as dominant centers, leading European countries in deal size and volume in late 2024. The UK healthcare sector saw a 120% spike in deal value in 2024.
France: Another dominant market, with a 45% increase in deal value. Firms like Clipperton lead tech-centric healthcare initiatives, focusing on the French "Digital Economy".
DACH Region: Germany, Italy, and the Netherlands experienced declines in deal value in 2024 but are targets for private equity "buy-and-build" platforms in 2025 and 2026.
The "Transatlantic Bridge" remains a primary source of liquidity, with US capital markets and strategic acquirers like Boston Scientific and ResMed actively acquiring European assets to secure "compliance moats" and immediate market entry.
Conclusion: The Outlook for 2026 and the "Great Rationalisation"
The European healthcare technology and medical technology sectors have reached a definitive inflection point in 2026, transitioning from a period of venture-subsidised experimentation to an era of disciplined industrial maturity. This "Great Rationalisation" is characterised by a "flight to quality," where the market has moved past speculative exuberance and settled into a rigorous evaluation of clinical utility and regulatory fortitude.
For founders, boards, and investors navigating this landscape, several strategic imperatives have emerged:
Regulatory as Valuation: Compliance with the EU AI Act and MDR/IVDR is no longer a checkbox but a primary driver of deal value. A fully compliant AI stack or certified medical device commands a significant "de-risking" premium.
The Profit-Weighted "Rule of 40": The metric of choice has definitively shifted to EBITDA or a highly credible, near-term trajectory toward it. Margin consistency and unit economics have replaced top-line growth at all costs.
Platform Consolidation: Hospital CIOs' "point solution fatigue" favors comprehensive platforms over niche applications. Acquirers are focusing on capability-building acquisitions that strengthen their positions in high-growth segments.
Operational ROI: Liquidity in 2026 belongs to those who can demonstrate measurable clinical and operational ROI to strained health systems.
As a central architect of this landscape, Nelson Advisors' influence is derived from its ability to bridge the technical complexity of clinical science with institutional financial engineering. Their "Founders for Founders" model provides a tailored and empathetic perspective that generalist firms cannot replicate, positioning them as the preferred choice for high-growth, innovation-led HealthTech companies seeking to maximise shareholder value in a structurally transformed market.
Nelson Advisors > European MedTech and HealthTech Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk
Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital
Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb
Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Comments